inclisiran

Inclisiran sodium (ALN-PCSsc sodium) is a dual-strand siRNA conjugated with triantennary N-acetylgalactosamine (GalNAc), with antihypertensive activity. It inhibits the transcription of PCSK9, reducing the hepatic synthesis of proprotein convertase subtilisin kexin type 9, and can be used in cardiovascular disease research.

Inclisiran (ALN-PCSsc), a double-stranded small interfering RNA (siRNA) compound, serves as the antisense of itself and targets PCSK-9 transcription inhibition. It is employed in the study of hyperlipidemia and cardiovascular disease (CVD) [1].

Inclisiran AS(3n-2), an antisense variant of Inclisiran, features a 2 bp spacer followed by 3 random N sites. Inclisiran itself is a double-stranded small interfering RNA (siRNA) molecule designed to suppress PCSK-9 transcription, thereby reducing LDL cholesterol levels [1].

Inclisiran (unconjugated naked) is a double-stranded small interfering RNA (siRNA) that lacks GalNAc conjugation. This compound selectively inhibits the transcription of PCSK-9, making it applicable in the research of hyperlipidemia and cardiovascular disease (CVD) [1].